Overview

Innoviva, Inc. is a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI).

Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Royalties Earned

royalties

Press Releases

Date Title and Summary
Toggle Summary Innoviva Reports Second Quarter 2021 Financial Results
Royalties increased by 44% to $104.3 million in the second quarter of 2021, compared to the same quarter in 2020. Repurchased GSK’s full 32% equity stake in Innoviva for $392 million purchase price. Strategically invested an additional $20 million into Entasis Therapeutics Holdings Inc.
Toggle Summary Innoviva Announces Strategic Repurchase of GSK’s Equity Stake
Innoviva to repurchase GSK’s current 32% stake in the company for $392 million BURLINGAME, Calif. --(BUSINESS WIRE)--May 20, 2021-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK’s equity stake in Innoviva ,
Toggle Summary Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately $7.5
Toggle Summary Innoviva Reports First Quarter 2021 Financial Results
Royalties increased by 8% to $89.0 million in the first quarter of 2021, compared to the same quarter in 2020. Invested an additional $20.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP), an anti-infectives leader, in the first quarter of 2021. Deborah L.
Presentations & Events
There are currently no events to display.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-486-9500

For business development inquiries,
please contact investor.relations@inva.com.